23:12 , Apr 13, 2017 |  BC Week In Review  |  Company News

Alteogen, Qilu deal

Alteogen granted Qilu exclusive, Chinese rights to develop and market ALT-L2 , a biosimilar of cancer drug Herceptin trastuzumab from Roche (SIX:ROG; OCTQX:RHHBY, Basel, Switzerland). Alteogen is eligible for undisclosed milestones and royalties. Alteogen declined...
23:38 , Nov 21, 2016 |  BioCentury  |  Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Company News

Alteogen, 3SBio deal

Alteogen granted 3SBio exclusive rights to develop and commercialize ALT-P7 in China, including Hong Kong and Macau. The preclinical antibody-drug conjugate inhibitor of EGFR2 ( HER2 ; ErbB2 ; neu) is based on Alteogen’s NexMab...